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Globally, thyroid cancer accounts for 2 % of all cancer diagnoses, and can be classified as well-differentiated or 
undifferentiated. Currently, differentiated thyroid carcinomas have good prognoses, and can be treated with a 
combination of therapies, including surgical thyroidectomy, radioactive iodine therapy and hormone-based ther-
apy. On the other hand, anaplastic thyroid carcinoma, a subtype of undifferentiated thyroid carcinoma character-
ized by the loss of thyroid-like phenotype and function, does not respond to either radioactive iodine or hormone 
therapies. In most cases, anaplastic thyroid carcinomas are diagnosed in later stages of the disease, deeming them 
inoperable, and showing poor response rates to systemic chemotherapy. Recently, treatment courses using multi-
ple-target agents are being explored and clinical trials have shown very promising results, such as overall survival 
rates, progression-free survival and tumor shrinkage. This review is focused on thyroid carcinomas, with particular 
focus on anaplastic thyroid carcinoma, exploring its undifferentiated nature. Special interest will be given to the 
treatment approaches currently available and respective obstacles or drawbacks. Our purpose is to contribute to 
understand why this malignancy presents low responsiveness to current treatments, while overviewing novel ther-
apies and clinical trials. 
 





The thyroid is a butterfly-shaped gland 
composed by two lobes, located medially in 
front of the neck, below the larynx and poste-
riorly to the tracheal thyroid cartilage 
(Stathatos, 2006). This gland has a functional 
unit, the thyroid follicle, a cystic structure 
composed of a single layer of follicular cells 
(Stathatos, 2012). These units store thyro-
globulin, involved in the synthesis of thyroid 
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hormones (i.e., tri-iodothyronine, T3; and 
tetraiodothyronine, T4) (Rousset et al., 2000; 
Stathatos, 2012). Thyroid hormone produc-
tion and secretion are controlled by the hypo-
thalamus-pituitary axis, comprising the re-
lease of thyrotropin-releasing hormone 
(TRH) from the hypothalamus, and thyroid-
stimulating hormone (TSH), from the pitui-
tary (Opitz et al., 2009; Stathatos, 2012). 
Upon release by the pituitary, TSH binds to 
the TSH receptor (TSHR) of the follicular 
cells’ membrane, stimulating the synthesis 
and release of the thyroid hormones (Opitz et 
al., 2009; Stathatos, 2012). Regulation of thy-
roid function is achieved almost entirely by a 
negative feedback mechanism carried out by 
T3 and T4 on hypothalamus and pituitary.  
T3 and T4 are known to play important 
roles in the human body, such as promoting 
the growth and differentiation of many tis-
sues, as well as energy and metabolic homeo-
stasis, due to their involvement in different 
metabolic pathways (Jugan et al., 2010). 
Moreover, the thyroid gland also comprises 
neural-crest derived parafollicular C-cells, lo-
cated in-between thyroid follicles and respon-
sible for calcitonin secretion (Khan and 
Farhana, 2020). This hormone promotes cal-
cium and phosphate deposition in different 
tissues (Khan and Farhana, 2020).  
Although thyroid cancers account for only 
2.1 % of all cancers diagnosed worldwide, it 
is one of the most frequent endocrine malig-
nancies (Gimm, 2001; Kitahara and Sosa, 
2016; Nikiforova and Nikiforov, 2008). As 
with other malignancies, thyroid cancers dif-
fer in their morphology, invasiveness and mo-
lecular profile (Lin, 2011; Nikiforova and 
Nikiforov, 2008).  
Taking into account their histopathology, 
thyroid carcinomas can be classified as well-
differentiated (medullary, papillary and fol-
licular thyroid carcinoma) or undifferentiated 
(anaplastic thyroid carcinoma) (Kondo et al., 
2006; Lin, 2011; Soares et al., 2011), as sum-
marized in Table 1. 
 
 
Table 1: Classification of thyroid carcinomas 
Cell type Subtype 
Unknown  Anaplastic TC Undifferen-
tiated Follicular 
Papillary TC Well-differ-




TC – Thyroid Carcinoma 
 
EPIDEMIOLOGY AND PROGNOSIS 
Papillary thyroid carcinoma accounts for 
the largest portion of thyroid carcinomas (70-
80 %), being the least aggressive due to 
slowly-forming metastasis and low invasive-
ness (Nguyen et al., 2015). Follicular thyroid 
carcinoma is a more aggressive subtype of 
well-differentiated thyroid carcinoma, due to 
its usual later diagnosis, and accounts for 
10 % of thyroid malignancies (D'Avanzo et 
al., 2004). Medullary thyroid carcinoma ac-
counts for 5-10 % of thyroid malignancies, 
originates from parafollicular C-cells, is asso-
ciated with a mutation of the RET proto-onco-
gene and can be sporadic or familial (25 % of 
medullary thyroid carcinomas) (Leboulleux 
et al., 2004). Another form of hereditary thy-
roid carcinoma is familial non-medullary thy-
roid carcinoma, englobing all hereditary thy-
roid carcinomas originating from thyroid fol-
licular cells (Nosé, 2008; Robenshtok et al., 
2011). Although familial non-medullary thy-
roid carcinoma is inherited through an auto-
somal dominant pattern, the associated mu-
tated genes are not yet identified (Robenshtok 
et al., 2011).  
Anaplastic thyroid carcinoma is a form of 
undifferentiated thyroid carcinoma, which 
although rare (<2 %), is one of the most lethal 
malignancies, being characterized by high ag-
gressiveness, due to both fast growth and 
strong invasiveness, as well as low respon-
siveness to most therapies currently available 
(Kebebew et al., 2005; Wiseman et al., 2003). 
Moreover, although anaplastic thyroid carci-
noma arises from thyroid follicular cells, 
these cells loose its thyroid-like features, 
leading to very poor prognosis (Lang and Lo, 
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2007). The overall 5-year survival rate upon 
anaplastic thyroid carcinoma diagnosis is 
lower than 10 %, and most patients do not live 
longer than a few months after diagnosis (Liu 
et al., 2016). 
These two groups of malignancies have 
different aggressiveness. Indeed, well-differ-
entiated thyroid carcinomas are known to be 
more manageable, with higher survival rates, 
whereas undifferentiated thyroid carcinomas 
are known to be more aggressive, with higher 
invasiveness and poorer prognosis, normally 
non-operable and having poor treatment re-
sponse rates (DeLellis, 2006). Well-differen-
tiated thyroid carcinomas include malignan-
cies derived from the thyroids’ follicular 
cells, such as papillary and follicular thyroid 
carcinomas (Soares et al., 2004). Anaplastic 
thyroid carcinoma is an undifferentiated sub-
type with very poor survival prognosis, esti-
mated to be 3 to 5 months after diagnosis, and 
survival rates of 10-20 % and less than 5 % 
after 1 and 10 years, respectively (Nagaiah et 
al., 2011). Although this rare tumor has an in-
cidence of only 1-2 persons per million per 
year, it is responsible for 40 % of all thyroid 
cancer deaths (Green et al., 2006; Tiedje et al., 
2018). The very poor prognosis is associated 
to anaplastic thyroid carcinoma only being 
detectable by the current diagnostic tools at 
advanced stages and, furthermore, being un-
responsive to the current treatments available 
(Lin, 2011).  
In similarity to what is seen for malignan-
cies of other tissues and/or organs, there are 
risk factors associated with the increased 
chances of developing thyroid carcinomas. 
Such risk factors include radiation exposure 
to the chest or neck area, abnormal iodine in-
take leading to iodine deficits, previously-ex-
isting thyroid pathologies (i.e., goiter and 
Hashimoto’s Thyroiditis) and metabolic dis-
orders (i.e., diabetes and obesity) (Liu et al., 
2017). There are some etiologic factors spe-
cifically associated with the development of 
anaplastic thyroid carcinoma, both as primary 
disease or by dedifferentiation of other thy-
roid malignancies. Such etiological factors in-
clude irradiation and abnormal TSH levels 
(Khairy, 2009). The biggest risk factor for de-
veloping this rare undifferentiated carcinoma 
seems to be prior history of goiter, both of self 
and familial (Nagaiah et al., 2011). Further-
more, risk factors generally include previous 
history of other thyroid malignancies, as these 
can give rise to anaplastic thyroid carcinoma 
through dedifferentiation (Dackiw, 2010; 
Khairy, 2009). Anaplastic thyroid carcinoma 
seems to occur most frequently in the elderly, 
being diagnosed at around 65-72 years old 
(Zivaljevic et al., 2014). Generally, both well-
differentiated and anaplastic thyroid carcino-
mas affect women 2 to 3 times more than men 
(Tuttle et al., 2010).  
 
PATHOPHYSIOLOGY AND  
HISTOLOGY 
As previously mentioned, based on their 
histology and behavior, thyroid carcinomas 
can be subcategorized in well-differentiated 
and undifferentiated (anaplastic) thyroid car-
cinomas. Regarding histology, well-differen-
tiated thyroid carcinoma arises from the thy-
roids’ follicular cells and can be classified as 
papillary, if a papillary pattern is seen, or fol-
licular, if a follicular pattern is found (Shah, 
2015). Although both patterns may be pre-
sent, classification is based on the most prev-
alent pattern observed (Shah, 2015). Further-
more, well-differentiated thyroid carcinoma 
aggressiveness is determined by assessing the 
presence of capsular and/or blood vessels in-
vasion (Filetti et al., 2019). Usually, papillary 
thyroid carcinomas present as an encapsu-
lated mass, not invasive, whereas the follicu-
lar subtype presents high invasiveness, of 
both capsule and blood vessels. Papillary thy-
roid carcinomas can be further distinguished 
into two classes according to molecular pro-
filing: BRAF-predominant; and RAS-predom-
inant, the last associated with increased ag-
gressiveness (Filetti et al., 2019).  
Usually, thyroid carcinoma staging is de-
termined by age, histology, size, extra-glan-
dular invasion and presence of distance me-
tastasis (Cady, 1998). Regardless of the pa-
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tient’s and tumor status based on the men-
tioned characteristics, anaplastic thyroid car-
cinomas are always classified as stage IV 
(Kebebew et al., 2005; Nguyen et al., 2015; 
Tahara et al., 2017). Then, by assessing dif-
ferent parameters, it can be sub-classified as: 
stage IVA, if it is confined to the thyroid; 
stage IVB, when there is extra thyroidal dis-
ease; or stage IVC, once distant metastasis are 
present (Ranganath et al., 2015). 
Anaplastic thyroid carcinoma is often 
clinically characterized as a large palpable 
rapidly growing mass, causing symptoms 
such as hoarseness, dysphagia, dyspnea, and 
in advanced cases, superior vena cava syn-
drome and Horner’s syndrome (Cabanillas et 
al., 2016; Wein and Weber, 2011). Histologi-
cally, the characteristic cells of this tumor are 
known to have undergone epithelial-mesen-
chymal cell phenotype transition (Lin, 2011). 
Furthermore, histological findings may fol-
low one of three patterns according to the 
main cellular population present being giant, 
spindle or squamous cells (Cabanillas et al., 
2016; Wein and Weber, 2011). This leads to 
uncertainty of the organ of origin, culminat-
ing in delays in diagnostic and in initiation of 
treatment (Cabanillas et al., 2016; Wein and 
Weber, 2011). Although these histological 
differences may be present, they do not sig-
nificantly influence prognosis (Are and 
Shaha, 2006). Macroscopically, regardless of 
its cellular heterogeneity, anaplastic thyroid 
carcinoma presents characteristically as large 
light tan color tumors, with marked invasive-
ness and mitotic activity, high proliferation, 
presence of hemorrhage and large areas of ne-
crotic tissue, but decreased apoptosis (Are 
and Shaha, 2006).  
Although this undifferentiated malig-
nancy can arise primarily, there is clinical, 
pathologic and epidemiologic evidences sup-
porting that it can originate from the dediffer-
entiation of previously-existing well-differen-
tiated thyroid carcinomas (Neff et al., 2008; 
Nikiforov, 2004). Such evidence includes the 
fact that these tumors can coexist and that 
some treated well-differentiated thyroid car-
cinomas relapse as anaplastic thyroid carcino-
mas (Santarpia et al., 2008). Furthermore, the 
genetic modifications and oncogenes that 
give rise to follicular and/or papillary thyroid 
carcinomas are also observed in anaplastic 
thyroid carcinomas (Neff et al., 2008; 
Nikiforov, 2004; Wang et al., 2007). Moreo-
ver, anaplastic thyroid carcinoma harbors 
some characteristic genetic features (Ragazzi 
et al., 2014). For example, gain of function 
mutations of the PIK3CA gene are frequently 
seen in anaplastic thyroid carcinoma, but not 
in well-differentiated thyroid carcinomas 
(Ragazzi et al., 2014). Mutations in the gene 
encoding -Catenin, CTNNB1, are commonly 
associated with epithelial-mesenchymal tran-
sition, which has been speculated as being one 
of the main processes behind this malignancy 
pathogenesis (DeLellis, 2006; Ragazzi et al., 
2014). The previously mentioned mutations 
are gain of function of important oncogenes, 
but the loss of function and inactivation of tu-
mor suppressor genes are also present in ana-
plastic thyroid carcinoma (Ragazzi et al., 
2014; Salvatore et al., 2007). Such genes in-
clude p53 and PTEN, both negative regulators 
of proliferation and inducers of apoptosis 
(DeLellis, 2006; Quiros et al., 2005; Salvatore 
et al., 2007). Thus, the inactivity of these 
genes lead to increased aggressiveness, and 
are present in this non-differentiated tumor 
(Ragazzi et al., 2014). Anaplastic thyroid car-
cinoma shares mutations with follicular and/ 
or papillary thyroid carcinomas, such as point 
mutations in BRAF and RAS, but these muta-
tions are more common in the differentiated 
subtypes (Antonelli et al., 2008; Ragazzi et 
al., 2014; Salvatore et al., 2007). Furthermore, 
the overexpression of receptors, such as epi-
dermal growth factor receptor (EGFR), are 
not only characteristic of anaplastic thyroid 
carcinoma but also of thyroid and primary 
thyroid carcinomas dedifferentiation or ana-
plastic carcinoma transformation (Fisher et 
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Well-differentiated thyroid carcinomas, 
such as follicular or papillary thyroid carcino-
mas, are usually asymptomatic and are diag-
nosed upon physical and/or ultrasonography 
examination (Paschke et al., 2015). In rare oc-
casions, well-differentiated thyroid carcino-
mas may present symptoms such as a palpable 
and growing neck mass, hoarseness, dyspha-
gia and/or with cervical lymph-node metasta-
ses (Paschke et al., 2015).  
Anaplastic thyroid carcinoma generally 
presents more serious symptoms, including 
hoarseness, airway distress, dyspnea and dys-
phagia, caused by a fast growing neck mass 
(Akaishi et al., 2011; Shaha, 2008). 
In order to classify a thyroid nodule as 
malignant or benign, TSH serum levels are 
evaluated, and a combination of histologic, 
cytologic and imaging techniques are used. 
TSH serum levels allow to differentiate be-
tween hyperfunctioning and non-functioning 
nodules (Nguyen et al., 2015). Thyroid carci-
nomas often present non-functioning thyroid 
nodules, and thus, other tests are generally re-
quired (Nguyen et al., 2015).  
Definitive diagnostic is usually achieved 
by fine-needle aspiration biopsy and/or high-
resolution ultrasonography (Huang et al., 
2015; Lewinski et al., 2000; Nguyen et al., 
2015). Papillary, medullary and anaplastic 
thyroid carcinomas are diagnosed according 
to the results of these examinations, but addi-
tional histological tests can be necessary to 
differentiate between follicular thyroid carci-
noma and benign follicular thyroid adenomas 
(Sherman, 2003). 
 
CURRENT TREATMENT  
APPROACHES 
Currently, thyroid cancer is treated by us-
ing a combination of radioactive iodine ther-
apy, thyroid hormone suppression therapy 
and surgery. Nevertheless, the chosen treat-
ment is defined according to different factors, 
such as the subtype of cancer and stage of dis-
ease (Nguyen et al., 2015).  
Total or partial surgical resection of the 
thyroid gland remains one of the first options 
for both well-differentiated and undifferenti-
ated thyroid carcinomas, although in the latter 
total thyroidectomy is unusual due to inva-
siveness of the disease (Cabanillas et al., 
2016; Giuffrida and Gharib, 2000). 
Therapy with radioactive iodine has been 
used to treat thyroid cancer since 1946 (Lee, 
2010). For radioactive iodine therapy to be ef-
fective, a high level of thyroid-stimulating 
hormone (TSH or thyrotropin) must be pre-
sent in the blood to promote its uptake/or ab-
sorption. To synthetize thyroid hormones, the 
thyroid follicular cells need to uptake iodine, 
a substrate required for the synthesis of these 
hormones. Iodine is internalized by the follic-
ular cells through iodine symporter channels. 
Inside the follicular cells, the iodine is oxi-
dized and bound to tyrosyl residues of thy-
roglobulin, giving rise to tri-iodothyronine 
(T3) and tetraiodothyronine (T4), with three 
and four atoms of iodine, respectively (Biondi 
et al., 2005; Ross, 2011). When in the pres-
ence of Radioactive Iodine (131I) instead of 
normal iodine, the 131I undergoes the previ-
ously described processes in the follicular 
cells, leading to tissue necrosis mediated by 
its beta emissions. As a result, this necrosis 
will lead to the ablation of the functional tis-
sues of the thyroid gland (Ross, 2011; 
Schlumberger et al., 2014). Conventionally, 
this therapy is used after surgery, either as an 
adjuvant therapy or to treat any tumoral resid-
ual tissue (Jonklaas et al., 2006; Sawka et al., 
2004). Undifferentiated and medullary thy-
roid carcinomas do not respond to this therapy 
as they are characterized by a lack of expres-
sion of thyroid cell markers and behavior, be-
ing unable to uptake iodine and consequently 
produce T3 and T4 (Cabanillas et al., 2016; 
Sherman, 2003). 
Usually, life-long thyroid hormone ther-
apy (THST) is used to treat well-differenti-
ated and medullary thyroid carcinomas after 
thyroidectomy and radioactive iodine therapy 
to prevent thyroid-stimulating hormone 
(TSH)-dependent proliferation of any resid-
ual well-differentiated thyroid cancer cells 
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(Brabant, 2008; McGriff et al., 2002; 
Sherman, 2003). Physiologically, TSH re-
lease by the pituitary is inhibited by high se-
rum levels of T3 and T4, i.e., through a nega-
tive feedback mechanism (Biondi et al., 
2005). Thus, this therapy involves the admin-
istration of T3 and T4, increasing serum levels 
of these two hormones and inhibiting pituitary 
TSH release (Biondi et al., 2005). Moreover, 
besides inhibiting TSH-dependent proliferat-
ion of cancer cells, THST also corrects the 
surgically-induced hypothyroidism of pa-
tients who undergo total or partial thyroid re-
section (Biondi et al., 2005).  
Medullary thyroid carcinomas and undif-
ferentiated thyroid carcinomas are usually un-
responsive to the conventional course of ther-
apy used for well-differentiated thyroid carci-
nomas: radioactive iodine therapy, THST and 
surgery (Sherman, 2010). For this reason, sys-
temic chemotherapy is used for the treatment 
of the mentioned malignancies, and also for 
the treatment of non-resectable, radioactive-
iodine-non-responsive, recurrent or meta-
static, well-differentiated thyroid carcinomas 
(Busaidy and Cabanillas, 2012; Sherman, 
2010).  
 
Treatment of well-differentiated thyroid 
carcinomas 
Currently, well-differentiated (papillary 
and follicular) thyroid carcinomas are treated 
by using a combination of surgery to remove 
the thyroid and, if necessary, radioactive io-
dine therapy and THST. It has been reported 
that patients with stage II or well-differenti-
ated high-risk thyroid carcinoma benefit from 
radioactive iodine therapy, improving their 
overall survival (Jonklaas et al., 2006). This is 
not the case for patients with stage I well-dif-
ferentiated thyroid carcinomas, whose overall 
survival worsens when 131I is used (Jonklaas 
et al., 2006). Furthermore, radioactive iodine 
therapy can also be useful for patients with 
metastatic disease, in which the distant neo-
plastic foci have thyroid-like features, re-
sponding to treatment and 131I uptake 
(Cabanillas et al., 2016). Thus, although radi-
oactive iodine therapy is efficient in many 
cases, it has severe side effects associated to 
it such as off-target organ damage (i.e., sali-
vary glands and bone marrow) and increasing 
the patients risk of developing hematologic 
malignancies (Kloos, 2009).  
Furthermore, THST has been shown to be 
an efficient therapy for the treatment of well-
differentiated thyroid carcinomas, increasing 
the patients’ overall survival, reducing dis-
ease recurrence and cancer-related mortality 
(Cabanillas et al., 2016; Jonklaas et al., 2006). 
Moreover, high-risk well-differentiated thy-
roid carcinoma patients strongly benefit from 
this therapy, whose survival can be increased 
2 to 3 fold-factor (Sherman, 2003).  
In the case of metastatic and/or advanced 
well-differentiated thyroid carcinomas, sys-
temic chemotherapies are used. But, unfortu-
nately, these malignancies are associated with 
poor response rates and short time of response 
when systemic therapies are used (Pacini et 
al., 2010). Some of the cytotoxic drugs used 
for the treatment of advanced thyroid carci-
noma include doxorubicin, paclitaxel, tamox-
ifen, bleomycin, epirubicin, cisplatin and oc-
treotide (Harada et al., 1971; Liebner et al., 
2016; Pacini et al., 2010; Sherman, 2003, 
2010). The choice of systemic therapies is 
somewhat inconclusive, as reports with dif-
ferent response rates to the same protocols are 
observed. For example, doxorubicin, the most 
studied and used chemotherapy agent for 
these malignancies, seems to be one of the cy-
totoxic drugs with the highest response rate, 
~40 %; but this response is temporary and 
most responses to this drug are incomplete 
(Sherman, 2003). Other studies show that 
some patients only have a response rate of 
~17 %, for the single use of doxorubicin, dis-
playing however, an increase in response 
rates when combined with cisplatin or even 
achieving complete responses (Lim, 2012; 
Shimaoka et al., 1985). Altogether, doxorubi-
cin seems to be the most effective in treating 
metastatic disease, that are non-responsive to 
other treatments, as well as for medullary thy-
roid carcinoma, either as a single-agent chem-
otherapy or in combination with other agents 
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(Liebner et al., 2016). Such combined regi-
mens include: doxorubicin, bleomycin and 
vincristine; or bleomycin, doxorubicin and 
cisplatin (Liebner et al., 2016). 
When administered at low doses, cyto-
toxic agents can be used as radiosensitizers 
for external radiation therapy to increase its 
efficacy (Lim, 2012).  
 
Treatment of anaplastic thyroid carcinoma 
According to the most recent American 
Thyroid Association (ATA) guidelines, to 
manage and control local and metastatic ana-
plastic thyroid carcinoma, a combination of 
surgery, chemotherapy and radiotherapy 
should be used (Smallridge et al., 2012). Sur-
gery for local disease management should be 
applied when total or major part of the mass 
is resectable, without damaging the surround-
ing vital structures (i.e., trachea, larynx, vocal 
cords, esophagus, major vessels and nerves, 
etc.). ATA also describes that only a small 
percentage of patients fit these criteria. In pal-
liative care, surgery can improve quality of 
life, for example by decompressing the pa-
tient’s airway. Regardless of potential-cura-
tive or palliative intent of treatment, trache-
ostomy is recommended by ATA for airway 
management (Ranganath et al., 2015). As ad-
juvant or primary course of treatment, radio- 
and chemotherapy are also used. Different cy-
totoxic drugs are used, such as regimens com-
bining paclitaxel and carboplatin, or docet-
axel and doxorubicin, but multimodal chemo-
therapy regimens composed of only one cyto-
static drug, such as cisplatin, paclitaxel and 
doxorubicin, are also part of the therapeutic 
options. In the case of advanced metastatic 
disease, surgery and radiotherapy are not rec-
ommended, being the systemic therapies the 
most appropriate. 
For this, anthracyclines and platins are 
used as first-line cytotoxic chemotherapy reg-
imens. Overall survival seems to be maxim-
ized when the three presented therapeutic op-
tions are combined (Molinaro et al., 2017). 
Although the above-described therapeutic 
options are available, both individually and 
combined, its efficacy in treating and curing 
patients with anaplastic thyroid carcinoma is 
very low (Molinaro et al., 2017). For exam-
ple, although it has been described that total 
resection of tumor increases 1 year survival to 
92 %, the mean survival of patients that un-
dergo surgery is 3.5 months (Smallridge and 
Copland, 2010). Radiotherapy alone does not 
seem to improve survival (2.3 months), but in 
combination with surgery and chemotherapy, 
survival rates of 2 years after diagnosis, for 
some patients, are reported (Nagaiah et al., 
2011; Smallridge and Copland, 2010).  
Radiotherapy has no effect in disease re-
occurrence, with half of the patients relapsing 
when treated with radiotherapy alone (Small-
ridge and Copland, 2010). Due to the recur-
rence rate, cytotoxic agents such as doxorubi-
cin, can also be used as radiosensitizers, im-
proving local long-term control rate (68 %). 
Although this cytotoxic agent is the most used 
in chemotherapy regimens for anaplastic thy-
roid carcinoma, its response rate is around 
22 % (Molinaro et al., 2017; Nagaiah et al., 
2011; Smallridge and Copland, 2010). 
Paclitaxel and docetaxel, also used in chemo-
therapy regimens, show a response rate of 
around 53 and 14 %, respectively (Molinaro 
et al., 2017; Nagaiah et al., 2011). Regimens 
composed of only cisplatin, bleomycin and 
methotrexate also have poor response rates 
(Nagaiah et al., 2011). The poor response 
rates presented might be due to anaplastic thy-
roid carcinoma expressing multidrug re-
sistance-associated proteins and due to the 
presence of cancer stem cells (Haghpanah et 
al., 2016; Nagaiah et al., 2011). Although sys-
temic treatment with chemotherapy has 
achieved promising results, combining doxo-
rubicin and cisplatin seems to be more effec-
tive in reducing mass size, being, for this rea-
son, the standard systemic therapeutic regi-




To overcome the lack of both efficacy and 
tumor selectivity, nanosystems-based thera-
peutical approaches have been developed 
with promising results. One example is the 
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copper-based nanosystems for radiotherapy 
and Photothermal Therapy (PTT), used to 
treat thyroid carcinomas (Zhou et al., 2015). 
PTT is a non-pharmacologic and less invasive 
approach to target and reduce tumors by ther-
mal ablation of cancer cells, with minimal 
side effects when compared to other therapeu-
tic options (Silva et al., 2016b), as represented 
in Figure 1. A gold-based nano hybrid ap-
proach has been developed for the treatment 
of melanoma, also showing very promising 
results for the treatment of other tumors, such 
as anaplastic thyroid carcinoma (Silva et al., 
2016a, 2016b; Amaral, 2020). 
Moreover, an incoming therapeutic ap-
proach for the treatment of anaplastic thyroid 
carcinoma is using targeted inhibitors for hy-
peractive and/or mutant components of sig-
naling pathways (Saini et al., 2018). As previ-
ously mentioned, members of the RAF/ 
MAPK and MEK pathway are mutated in this 
malignancy (i.e., EGFR, BRAF, Ras) (Saini 
et al., 2018; Santarpia et al., 2008; Smallridge 
et al., 2009). Recent studies reported promis-
ing results, either of decrease in tumor mass 
or good responses, using targeted/multi-tar-
geted therapies, both individually or com-
bined, enlightening the benefits of using se-
quencing tools to identify possible targets for 
each patient (Tiedje et al., 2018). Further-
more, small-molecule tyrosine kinase inhibi-
tors, such as sorafenib (Nagaiah et al., 2011), 
vemurafenib (Rosove et al., 2013), dabrafenib 
(Subbiah et al., 2018), and trametinib 
(Subbiah et al., 2018), have been shown to be 
promising for the treatment of anaplastic thy-
roid carcinoma, being currently in clinical tri-
als, alone or in combination (i.e., dabrafenib + 
trametinib) (Nagaiah et al., 2011; Subbiah et 
al., 2018; Tiedje et al., 2018). However, when 
a small-molecule tyrosine kinase inhibitor 
was used alone, disease reoccurrence was re-
ported by most patients (Saini et al., 2018). 
Table 2 summarizes the promising results of 
completed clinical trials using small-mole-
cule tyrosine kinase inhibitors for the treat-
ment of anaplastic thyroid carcinoma. 
 
Figure 1: Different steps of PTT using a targeted hybrid gold-based nanosystem developed and a near-
infrared (NIR) laser, in a xenograft mice model. (A) In situ administration of hybrid nanosystem at the 
tumor site, specific for tumor cells (represented in a darker color); (B) Irradiation of the injected site with 
a NIR laser to activate the formulation; (C) Reduction of tumor mass through thermal ablation.
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Some of these therapeutic results dis-
played much higher response rates in compar-
ison to the current therapies used, being 10 
months the longest overall survival rate re-
ported. The 2-3-fold increase in overall sur-
vival corresponds to less than a year. 
Table 3 resents ongoing clinical trials 
(Phase I and II) registered on the ClinicalTri-
als.gov database, and its respective database 
ID, being conducted worldwide, using differ-
ent treatment approaches and protocols (i.e., 
radiotherapy, chemotherapy, immunotherapy, 
small-molecule tyrosine kinase inhibitors, 
and a combination of these therapies) for the 
treatment of anaplastic thyroid carcinoma. 
 
 
Table 2: Results of completed clinical trials using targeted or multi-target therapies for the treatment of 
anaplastic thyroid carcinoma 
Drug Target Main Outcomes Reference 
Everolimus mTOR PFS of 47 weeks; 63 % of pa-
tients reported tumor shrinkage. 
Lim et al., 2013 
 
Vemurafenib BRAF Complete clearance of metasta-
sis 38 days after treatment 
Rosove et al., 
2013 
Sunitinib Multi-targeted  
(i.e., RET, VEGFR) 
Significant decrease of neck 
mass, alleviating symptoms 




BRAF and MEK, respectively 69 % response rate Subbiah et al., 
2018 
Imatinib  Multi-targeted  
(i.e., Bcr-Abl, c-kit) 
45 % of patients had 6-months 
OS 
Ha et al., 2010 
Lenvatinib Multi-targeted (i.e., VEGFR, 
FGFR, PDGFRα, RET, KIT) 
PFS of 7.4 months 
OS of 10.6 months 
Tahara et al., 
2017 
Sorafenib Multi-targeted (i.e., VEGFR, 
RET, Raf, PDGFR) 
PFS of 77 weeks NCT00654238 
(clinicaltrials.gov)
PFS – Progression-Free Survival 
OS – Overall Survival 
 
Table 3: Ongoing clinical trials using targeted or multi-targeted therapies, radiotherapy, immunotherapy 
and chemotherapy for the treatment of anaplastic thyroid carcinoma 
Drug Target Clinical.gov ID Phase
Lenvatinib Multi-Targeted (i.e., VEGFR, 
FGFR, PDGFRα, RET, KIT) 
NCT02726503 II 
Trametinib + Paclitaxel MEK, BRAF NCT03085056 Early I 
Durvalumab + Tremelimumab + 
Stereotactic Body Radiotherapy 
PD-1 and CTL-4, respectively NCT03122496 I 
MLN0128 mTOR NCT02244463 II 
Pembrolizumab PD-1 NCT02688608 II 
Nexavar Multi-Targeted (i.e., RAF, MEK, 
ERK, VEGFR, PDGFR) 
NCT03565536 II 
Efatutazone + Paclitaxel PPAR γ NCT02152137 II 
Intensity-Modulated Radiation  
Therapy + Paclitaxel + Pazopanib 
Hydrochloride 
Multi-Targeted (i.e., VEGFR, 
PDGFR, c-kit) 
NCT01236547 II 
Atezolizumab + Bevacizumab +  
Cobimetinib + Paclitaxel +  
Vemurafenib 
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Although some advances have been done 
regarding the treatment of anaplastic thyroid 
carcinoma, it still presents low survival rates. 
There is an urgent need to improve the treat-
ment of this rare malignancy, in order to sig-
nificantly increase patients’ survival and their 
life quality improvement. Altogether, the best 
approach seems to be a more personalized 
multimodal course of treatment, since there is 
considerable variability of response to treat-
ments using targeted/multi-targeted therapies 
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